Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597446 | 1.00 | FASN (0.36) | FASNCCR5TSHRSMN1; SMN2MME | |
| SCHEMBL1908592 | 0.88 | FASN (0.35) | FASNCCR5TSHRSMN1; SMN2MME | |
| SCHEMBL597903 | 0.88 | FASN (0.35) | FASNCCR5TSHRSMN1; SMN2MME | |
| SCHEMBL4435733 | 0.88 | FASN (0.35) | FASNCCR5TSHRSMN1; SMN2MME | |
| SCHEMBL598408 | 0.88 | FASN (0.35) | FASNCCR5TSHRSMN1; SMN2MME | |
| SCHEMBL11993549 | 0.85 | KLK7 (0.43) | — | |
| SCHEMBL598277 | 0.83 | L3MBTL1 (0.37) | CCR5TSHRSMN1; SMN2LMNAHPGD | |
| SCHEMBL597038 | 0.83 | L3MBTL1 (0.37) | CCR5TSHRSMN1; SMN2LMNAHPGD | |
| SCHEMBL1908590 | 0.83 | L3MBTL1 (0.37) | CCR5TSHRSMN1; SMN2LMNAHPGD | |
| SCHEMBL598349 | 0.78 | HCRTR1 (0.39) | CCR5TSHRSMN1; SMN2MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121578-B1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-9206116-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-12-08 | — | — | US | disclosed |
| US-9206116-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-12-08 | — | — | US | disclosed |
| US-9206116-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-12-08 | — | — | US | disclosed |
| US-20150166468-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | NOVARTIS AG (CH) | 2015-06-18 | — | — | US | disclosed |
| US-20150166468-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | NOVARTIS AG (CH) | 2015-06-18 | — | — | US | disclosed |
| US-20150166468-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | NOVARTIS AG (CH) | 2015-06-18 | — | — | US | disclosed |
| US-8993785-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-8993785-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-8993785-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-8716495-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2014-05-06 | — | — | US | disclosed |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| EP-2121578-A2 | NEW PROCESS | Novartis AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008083967-A2 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | MME, REN, PAH | FASN 1532/4885CCR5 3372/4885TSHR 2857/4885 |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | MME, REN, PAH | FASN 1532/4885CCR5 3372/4885TSHR 2857/4885 |
| US-20150166468-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | MME, REN, PAH | FASN 1532/4885CCR5 3372/4885TSHR 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.